Tirzepatide may be more effective than semaglutide or liraglutide for weight loss, as it has a dual mechanism of action.

Tirzepatide is the active ingredient in Zepbound, approved by the Food and Drug Administration (FDA) specifically for weight loss. Semaglutide was initially approved under the brand name Ozempic ...

Tirzepatide was associated with better glycemic control and weight loss outcomes than semaglutide and insulin among patients with T2D.

Tirzepatide is approved for 3 indications in the US: type 2 diabetes, chronic weight management, and obstructive sleep apnea.

Once-weekly treatment with tirzepatide can produce clinically meaningful and sustained weight loss for at least three years ...

Current Status of GLP-1 Medications The FDA has officially determined that the shortage of both semaglutide and tirzepatide injection products is now resolved. Semaglutide: The FDA determined on ...

In this retrospective cohort study, tirzepatide dispensations were found to have increased significantly following approval ...

Among all antiobesity medications, the incremental cost-effectiveness ratios were $197,023 and $467,676 per quality-adjusted life-year for tirzepatide and semaglutide, respectively. HealthDay News ...

INDIANAPOLIS – The way people are accessing GLP-1 medications Semaglutide and Tirzepatide is going to become very limited after the drugs were taken off the FDA’s shortage list. Hundreds of ...

After approval, tirzepatide dispensations increased markedly among adults with type 2 diabetes prescribed glucose-lowering medications (GLMs) and among adults without diabetes prescribed ...

Hims & Hers Health, Inc.'s share price surged when a global shortage of tirzepatide / semaglutide - a rival GLP-1 drug by Novo Nordisk - was declared, by offering a "compounded" version.